Aurobindo Pharma Ltd informed that its Australian subsidiary received approval for the registration of 5mg and 10 mg Besylate Tyblate from Therapeutic Goods Administration (TGA), Government of Australia.
The tablets fall under the central nervous system therapeutic segment and is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in majority of patients.
This is Aurobindo's fourth approval from TGA, Australia.
